284 related articles for article (PubMed ID: 33848766)
1. Targeting Son of Sevenless 1: The pacemaker of KRAS.
Kessler D; Gerlach D; Kraut N; McConnell DB
Curr Opin Chem Biol; 2021 Jun; 62():109-118. PubMed ID: 33848766
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Son of Sevenless Homologue 1 (SOS1): Promising therapeutic treatment for KRAS-mutant cancers.
Chen T; Tang X; Wang Z; Feng F; Xu C; Zhao Q; Wu Y; Sun H; Chen Y
Eur J Med Chem; 2023 Dec; 261():115828. PubMed ID: 37778239
[TBL] [Abstract][Full Text] [Related]
3. Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction.
Hillig RC; Sautier B; Schroeder J; Moosmayer D; Hilpmann A; Stegmann CM; Werbeck ND; Briem H; Boemer U; Weiske J; Badock V; Mastouri J; Petersen K; Siemeister G; Kahmann JD; Wegener D; Böhnke N; Eis K; Graham K; Wortmann L; von Nussbaum F; Bader B
Proc Natl Acad Sci U S A; 2019 Feb; 116(7):2551-2560. PubMed ID: 30683722
[TBL] [Abstract][Full Text] [Related]
4. Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein-Protein Interaction.
Ketcham JM; Haling J; Khare S; Bowcut V; Briere DM; Burns AC; Gunn RJ; Ivetac A; Kuehler J; Kulyk S; Laguer J; Lawson JD; Moya K; Nguyen N; Rahbaek L; Saechao B; Smith CR; Sudhakar N; Thomas NC; Vegar L; Vanderpool D; Wang X; Yan L; Olson P; Christensen JG; Marx MA
J Med Chem; 2022 Jul; 65(14):9678-9690. PubMed ID: 35833726
[TBL] [Abstract][Full Text] [Related]
5. Targeting mutant KRAS.
Erlanson DA; Webster KR
Curr Opin Chem Biol; 2021 Jun; 62():101-108. PubMed ID: 33838397
[TBL] [Abstract][Full Text] [Related]
6. Selective apoptosis-inducing activity of synthetic hydrocarbon-stapled SOS1 helix with d-amino acids in H358 cancer cells expressing KRAS
Xu LL; Li CC; An LY; Dai Z; Chen XY; You QD; Hu C; Di B
Eur J Med Chem; 2020 Jan; 185():111844. PubMed ID: 31706640
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and bioevaluation of SOS1 PROTACs derived from pyrido[2,3-d]pyrimidin-7-one-based SOS1 inhibitor.
Wang K; Zhou Z; Ma X; Xu J; Xu W; Zhou G; Zhou C; Li H; Zheng M; Zhang S; Xu T
Bioorg Med Chem Lett; 2024 Jul; 107():129780. PubMed ID: 38714262
[TBL] [Abstract][Full Text] [Related]
8. Targeting RAS oncogenesis with SOS1 inhibitors.
Hillig RC; Bader B
Adv Cancer Res; 2022; 153():169-203. PubMed ID: 35101230
[TBL] [Abstract][Full Text] [Related]
9. Small molecule Son of Sevenless 1 (SOS1) inhibitors: a review of the patent literature.
Thompson SK; Buckl A; Dossetter AG; Griffen E; Gill A
Expert Opin Ther Pat; 2021 Dec; 31(12):1189-1204. PubMed ID: 34253125
[No Abstract] [Full Text] [Related]
10. One Atom Makes All the Difference: Getting a Foot in the Door between SOS1 and KRAS.
Ramharter J; Kessler D; Ettmayer P; Hofmann MH; Gerstberger T; Gmachl M; Wunberg T; Kofink C; Sanderson M; Arnhof H; Bader G; Rumpel K; Zöphel A; Schnitzer R; Böttcher J; O'Connell JC; Mendes RL; Richard D; Pototschnig N; Weiner I; Hela W; Hauer K; Haering D; Lamarre L; Wolkerstorfer B; Salamon C; Werni P; Munico-Martinez S; Meyer R; Kennedy MD; Kraut N; McConnell DB
J Med Chem; 2021 May; 64(10):6569-6580. PubMed ID: 33719426
[TBL] [Abstract][Full Text] [Related]
11. Direct inhibition of oncogenic KRAS by hydrocarbon-stapled SOS1 helices.
Leshchiner ES; Parkhitko A; Bird GH; Luccarelli J; Bellairs JA; Escudero S; Opoku-Nsiah K; Godes M; Perrimon N; Walensky LD
Proc Natl Acad Sci U S A; 2015 Feb; 112(6):1761-6. PubMed ID: 25624485
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of RAS: proven and potential vulnerabilities.
Zuberi M; Khan I; O'Bryan JP
Biochem Soc Trans; 2020 Oct; 48(5):1831-1841. PubMed ID: 32869838
[TBL] [Abstract][Full Text] [Related]
13. Targeting of SOS1: from SOS1 Activators to Proteolysis Targeting Chimeras.
Hamilton G; Stickler S; Rath B
Curr Pharm Des; 2023; 29(22):1741-1746. PubMed ID: 37073657
[TBL] [Abstract][Full Text] [Related]
14. Therapeutics Targeting Mutant KRAS.
Thein KZ; Biter AB; Hong DS
Annu Rev Med; 2021 Jan; 72():349-364. PubMed ID: 33138715
[TBL] [Abstract][Full Text] [Related]
15. Design of Orally-bioavailable Tetra-cyclic phthalazine SOS1 inhibitors with high selectivity against EGFR.
He H; Chen R; Wang Z; Qing L; Zhang Y; Liu Y; Pan W; Fang H; Zhang S
Bioorg Chem; 2023 Jul; 136():106536. PubMed ID: 37054529
[TBL] [Abstract][Full Text] [Related]
16. Discovery and Structure-Based Optimization of Benzimidazole-Derived Activators of SOS1-Mediated Nucleotide Exchange on RAS.
Hodges TR; Abbott JR; Little AJ; Sarkar D; Salovich JM; Howes JE; Akan DT; Sai J; Arnold AL; Browning C; Burns MC; Sobolik T; Sun Q; Beesetty Y; Coker JA; Scharn D; Stadtmueller H; Rossanese OW; Phan J; Waterson AG; McConnell DB; Fesik SW
J Med Chem; 2018 Oct; 61(19):8875-8894. PubMed ID: 30205005
[TBL] [Abstract][Full Text] [Related]
17. Translational relevance of SOS1 targeting for KRAS-mutant colorectal cancer.
Alem D; Yang X; Beato F; Sarcar B; Tassielli AF; Dai R; Hogenson TL; Park MA; Jiang K; Cai J; Yuan Y; Fernandez-Zapico ME; Tan AC; Fleming JB; Xie H
Mol Carcinog; 2023 Jul; 62(7):1025-1037. PubMed ID: 37042566
[TBL] [Abstract][Full Text] [Related]
18. Unique dependence on Sos1 in
You X; Kong G; Ranheim EA; Yang D; Zhou Y; Zhang J
Blood; 2018 Dec; 132(24):2575-2579. PubMed ID: 30377195
[TBL] [Abstract][Full Text] [Related]
19. Development of Son of Sevenless Homologue 1 (SOS1) Modulators To Treat Cancers by Regulating RAS Signaling.
Luo G; Wang B; Hou Q; Wu X
J Med Chem; 2023 Apr; 66(7):4324-4341. PubMed ID: 36987571
[TBL] [Abstract][Full Text] [Related]
20. Understanding SOS (Son of Sevenless).
Pierre S; Bats AS; Coumoul X
Biochem Pharmacol; 2011 Nov; 82(9):1049-56. PubMed ID: 21787760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
